David A. Flockhart (1952–2015) was a Scottish medical researcher who was a leader in the field of personalised medicine.[1] He was especially known for his work on factors affecting the use of tamoxifen to treat breast cancer such as variability in the level of the CYP2D6 enzyme.[2][3]
References
edit- ^ "In death, there is life", The Economist, p. 84, 26 March 2016
- ^ "David Flockhart : Obituary", Edinburgh Evening News, 3 December 2015
- ^ In Memoriam, David A. Flockhart PhD, MD, Indiana University Department of Medicine, 26 November 2015
 | This biographical article related to medicine is a stub. You can help Wikipedia by expanding it. |